In a report released today, Mara Goldstein from Mizuho Securities maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report), with a price target of $6.00. The company’s shares closed today at $0.79.
According to TipRanks, Goldstein is an analyst with an average return of -4.4% and a 32.53% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Merck & Company, Incyte, and Nektar Therapeutics.
In addition to Mizuho Securities, Nektar Therapeutics also received a Hold from SVB Securities’s Daina Graybosch in a report issued on April 18. However, on April 17, Goldman Sachs maintained a Sell rating on Nektar Therapeutics (NASDAQ: NKTR).
See Insiders’ Hot Stocks on TipRanks >>
NKTR market cap is currently $151.5M and has a P/E ratio of -0.41.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NKTR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More on NKTR:
- Nektar Chief Medical Officer Brian Kotzin, CFO Jillian Thomsen to step down
- Nektar announces strategic repriotization, to reduce San Francisco staff by 60%
- Nektar Therapeutics says no cash deposits, securities at Silicon Valley Bank
- Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
- Nektar reports Q4 EPS (32c), consensus (45c)
